Cargando…
Vascular disrupting agent for neovascular age related macular degeneration: a pilot study of the safety and efficacy of intravenous combretastatin a-4 phosphate
BACKGROUND: This study was designed to assess the safety, tolerability, and efficacy of intravenous infusion of CA4P in patients with neovascular age-related macular degeneration (AMD). METHODS: Prospective, interventional, dose-escalation clinical trial. Eight patients with neovascular AMD refracto...
Autores principales: | Ibrahim, Mohamed A, Do, Diana V, Sepah, Yasir J, Shah, Syed M, Van Anden, Elizabeth, Hafiz, Gulnar, Donahue, J Kevin, Rivers, Richard, Balkissoon, Jai, Handa, James T, Campochiaro, Peter A, Nguyen, Quan Dong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3552984/ https://www.ncbi.nlm.nih.gov/pubmed/23316779 http://dx.doi.org/10.1186/2050-6511-14-7 |
Ejemplares similares
-
Combretastatin-A4 disrupts neovascular development in non-neoplastic tissue
por: Griggs, J, et al.
Publicado: (2001) -
Therapies for Neovascular Age-Related Macular Degeneration: Current Approaches and Pharmacologic Agents in Development
por: Hanout, Mostafa, et al.
Publicado: (2013) -
Multitask Learning for Activity Detection in Neovascular Age-Related Macular Degeneration
por: Ayhan, Murat Seçkin, et al.
Publicado: (2023) -
Aflibercept: a Potent Vascular Endothelial Growth Factor Antagonist for Neovascular Age-Related Macular Degeneration and Other Retinal Vascular Diseases
por: Sophie, Raafay, et al.
Publicado: (2012) -
Management of neovascular age-related macular degeneration: current state-of-the-art care for optimizing visual outcomes and therapies in development
por: Agarwal, Aniruddha, et al.
Publicado: (2015)